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Key Clinical Message
We present a case of severe, irreversible neurotoxicity in a 55-year-old-patient
with myelofibrosis undergoing hematopoietic stem cell transplantation follow-
ing a reduced intensity conditioning including fludarabine. The patient devel-
oped progressive sensory-motor, visual and consciousness disturbances,
eventually leading to death. MRI imaging pattern was unique and attributable
to fludarabine neurotoxicity.
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Introduction
Fludarabine is a drug widely used in the treatment of
hematological malignancies, representing one of the main
components in the reduced intensity conditioning regi-
mens for hematopoietic stem cell transplantation. Ane-
mia, neutropenia, and thrombocytopenia due to
myelosuppression are the major adverse effects associated
with fludarabine administration [1]. Neurotoxicity is an
uncommon but well-known possible adverse event during
treatment with fludarabine.
Most of the published series on fludarabine neurotoxic-
ity derive from experiences around the middle of the
Eighties, where escalating doses were administered in
dose-finding studies; moreover, computed tomography
(CT) scans rather than magnetic resonance imaging
(MRI) were available as imaging counterparts. Subse-
quently, standard dose fludarabine and purine analogues
neurotoxicity has been seldom the matter of specific
reports [2]. Only recently, clinical and MRI aspects of a
possible specific neurotoxicity after standard dose fludara-
bine both in the treatment of hematologic malignancies
and in reduced intensity allogeneic hematopoietic stem
cell transplantation have been reported [3, 4]. We present
an additional case of possible severe fludarabine neuro-
toxicity fitting with the clinical and imaging features
described in the above-cited articles.
Case Presentation
A 55-year-old male patient was admitted on November
15, 2010 in our Bone Marrow Transplant Centre to
undertake hematopoietic stem cell transplantation
(HSCT) from a matched unrelated donor. He was
affected by rapidly progressive myelofibrosis with severe
pancytopenia, high transfusion requirement, and iron
overload despite iron-chelating therapy. Conditioning reg-
imen included thiotepa 5 mg/kg every 12 h for two doses
and fludarabine 30 mg/m2 per day for 6 days. Anti-thy-
mocyte globulin 2.5 mg/kg per day, was delivered on days
-3 and -2. Allogeneic hematopoietic stem cell infusion
was performed on November 24, 2010. Graft versus host
disease (GvHD) prophylaxis included standard dose
cyclosporine and short course methotrexate.
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Subsequent course was uneventful during the neutrope-
nic phase, the patient experienced a single febrile episode
rapidly resolving after starting empirical antibiotic ther-
apy. At day +28 after transplantation, the patient was
transfusion independent and chimerism analysis showed
full donor engraftment. On December 25, 2010, the
patient complained of bilateral symmetric proprioceptive
deficit at the lower extremities. On the ensuing days,
brain and spine CT scans were performed which did not
show any abnormality (Fig. 1); MRI was somewhat
delayed because of the mild clinical pattern and of severe
claustrophobia requiring deep sedation with anesthesio-
logic support. Somato-sensitive evocated potentials, elec-
troencephalogram (EEG) and electromyogram (EMG)
were normal. Relying on the possibility of cyclosporine
toxicity as the most probable cause, methylprednisolone
and mycophenolate were provisionally substituted for
cyclosporine on December 26, 2010. The clinical picture,
however, continued to worsen on the following days: a
proprioceptive deficit appeared also at the upper extremi-
ties while the level of leg proprioceptive deficit extended
up to the knee level. Moreover, some tactile deficit was
observed and the patient started to suffer from occasional
confusion episodes.
Differential diagnosis, investigations, and
treatment
On January 3, 2011 MRI of brain (Fig. 2) and spine was
eventually performed with deep sedation. The most
outstanding feature were “bilateral symmetric T2 – FLAIR
hyperintense lesions involving the posterior periventricu-
lar and supraventricular white matter; the lesions demon-
strated restricted diffusion suggesting cytotoxic edema
without enhancement.” Although primarily attributable to
toxicity, the imaging pattern did not fulfill the commonly
observed criteria for cyclosporine toxicity. Apart from
corticosteroids, the patient received high dose immuno-
globulins and hydrosoluble vitamin complex, without any
benefit. To confirm the toxicity hypothesis, a Positron
Emission Tomography (PET) scan was also performed,
failing to show hypermetabolic areas in the brain. On the
following days, the lesions became apparent also at the
CT scan as hypodense ones (Fig. 3); two subsequent CT
investigations showed only mild signs of worsening. The
patient repeatedly refused cerebrospinal fluid examina-
tion. Blood virus monitoring was negative, with the only
exception of a low number of JC and BK viruses DNA
copies detected, without any tendency towards an
increase.
Due to the lack of any benefit from its interruption,
cyclosporine was resumed after 1 week, not hindering
however the development of cutaneous, hepatic and intes-
tinal acute GvHD. Methylprednisolone dosage was then
escalated to 2 mg/kg, though allowing only cutaneous
GvHD to be controlled.
Outcome and follow-up
A significant improvement in intestinal GvHD was
achieved through the addition of the anti-TNF agent inf-
liximab, whereas hepatic GvHD showed a slowly progres-
sive, relentless course.
At the same time, the neurological picture worsened
jointly at sensitive, motor and cognitive level. The patient
became soon paraplegic, with sensitive deficit ostensibly
sparing only pain perception; eventually, he progressively
developed central blindness. At cognitive level, after a
protracted phase where the patient appeared delirious and
confused, he became barely contactable.
The patient died on March 12, 2011 from hepatic fail-
ure due to progressive acute GvHD.
Discussion
Fludarabine is a purine analogue, originally synthesized
by Montgomery and Hewson in 1969 [5], and used pri-
marily in the treatment of malignancies arising from the
clonal expansion of lymphocytes, particularly in B-chronic
lymphocytic leukemia (B-CLL) [6]; because of its potent
immunosuppressive activity, it is also used in the condi-
tioning regimens for allogeneic transplantation [7], partic-
ularly in those of reduced-intensity.
Figure 1. CT scan taken at the onset of symptoms failing to show
any abnormalities.
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From a pharmacokinetic point of view, it acts as a
“pro-drug,” requiring metabolic dephosphorylation to the
hydrophilic antimetabolite F-ara-A (9-beta-D-arabinosyl-
2-fluoroadenine), which can enter cells only in the pres-
ence of concentrative nucleoside transporters (CNTs);
within the cells, the enzyme deoxycytidine (CdR) kinase
progressively re-phosphorylates F-ara-A up to fludarabine
triphosphate (F-ara-ATP), the only metabolite displaying
cytotoxic activity [8]. Polymorphisms in the genes codify-
ing for CNTs or CdR kinase may cause, respectively,
different uptake and conversion rate, resulting in altered
fludarabine therapeutic index and risk of toxicity.
Cytotoxic activity of F-ara-ATP relays on the inactiva-
tion of DNA synthesis through the inhibition of several
specific enzymes (DNA polymerase, DNA primase, DNA
ligase, ribonucleotide reductase) [9]. The inactivation of
DNA synthesis is followed by an initiation of an apopto-
tic process leading to cell death [10]. Of note, F-ara-ATP
can induce death also in quiescent cells, via the activation
of the mitochondrial pathway of apoptosis [11].
Anemia, neutropenia and thrombocytopenia due to
myelosuppression are the main adverse effects associated
with fludarabine administration [1]. Severe neurotoxicity
likely related to the high activity of CdR kinase in the
Figure 2. MRI of brain. Axial T2 (upper left), DWI (lower left), and FLAIR (lower right), showing posterior periventricular high signal areas. Axial
T1 with contrast medium (upper right) showing no enhancement.
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brain is included among nonhematological fludarabine
side effects [12, 13].
Central and peripheral nervous system toxicity [14–16]
are possible side effects of several drugs, especially anti-
cancer agents, often directing to dose reduction or drug
withdrawal. Neurotoxicity may be severe and irreversible.
Central nervous system (CNS) toxicity presenting as
encephalopathy of different severity has been observed
not only after fludarabine administration but also with
other chemotherapeutic agents, such as vincristine, cis-
platin, methotrexate, cytarabine, ifosfamide, 5-fluoroura-
cil; on the other hand, peripheral neuropathy results most
frequently associated with taxanes, carboplatin, vincris-
tine, thalidomide, and bortezomib.
Several compounds have been proposed as neuropro-
tective agents against chemotherapy-induced neurotoxic-
ity, but few of them have been shown to be effective [17].
In an animal model, the incidence of fludarabine neuro-
toxicity was reduced by the coadministration of NBMPR-
P, 50-phosphate of nitrobenzyl-thioinosine, a potent
inhibitor of the nucleoside transport (NT) system.
NBTGR-P, the 50-phosphate of nitrobenzyl-thioguanosine
(also a potent NT inhibitor) similarly prevented F-
ara-AMP neurotoxicity in this experimental system [18].
Fludarabine is licensed and extensively used for the treat-
ment of CLL [1]. Moreover, it is commonly used for the
treatment of acute myeloid and lymphoblastic leukemia
(AML/ALL) together with cytarabine and filgrastim in the
setting of the “FLAG” schemes [19, 20]. More recently, it has
become the reference drug for allogeneic hematopoietic
stem cell transplantation following reduced intensity condi-
tioning regimens [21, 22]. Fludarabine-related neurotoxicity
was reported in up to 30–40% of patients in phase I/II stud-
ies, where the drug was frequently administered at daily
doses in excess of 100 mg/m2 for 5–7 days [13, 23–25]. High
dose fludarabine neurotoxicity was frequently reported as
irreversible and life-threatening, although milder cases were
not infrequent [26]. Rather surprisingly, despite the exten-
sive use of the drug, the interest on this field rapidly waned
over the subsequent decades, so that rather little is known
about the frequency as well as about the clinical and MRI
features of standard dose fludarabine neurotoxicity. Kornb-
lau and coworkers [27] reported 8 of 219 cases of neurotox-
icity, two being severe; a neutoxicity rate of 14%, benign and
reversible in most of the cases, was reported in a review by
Cheson et al. dealing with standard dose purine analogues
[2]. Subsequently, viral infections, including progressive
multifocal leukoencephalopathy (PML) [28–30], and better
established toxic events, as posterior reversible encephalopa-
thy syndrome (PRES) [31, 32], have been the matter of
reports in the field of either fludarabine therapy or reduced
intensity allogeneic hematopoietic stem cell transplantation
[33]. Concerning the latter, the specific role of fludarabine is
hard to be distinguished from that of the well-known neuro-
toxic immunosuppressive agent cyclosporine-A [34], and
from that of the total body irradiation (TBI), often included
in the conditioning regimens.
Four years ago, Beitinjaneh and collaborators [3]
reported acute toxic leukoencephalopathy (ATL) as a pos-
sible clinical and imaging counterpart of fludarabine neu-
rotoxicity. Not unlike to previous reports [13, 23–25], the
most common clinical features of ATL included cognitive
impairment associated with visual and sensitive defects;
the clinical outcome was frequently, but not always, irre-
versible and progressive; the MRI pattern was character-
ized by the presence of bilateral signal alterations in the
deep white matter, rather distinct from PRES. The classic
pattern of involvement in PRES is the presence of bilat-
eral and symmetric lesions in the cortex and subcortical
white matter of the occipital and parietal lobes [31, 32].
In the same year, Lee and colleagues [4] described in
more detail the clinical and MRI features of three patients
undergoing reduced intensity hematopoetic stem cell
transplantation and receiving fludarabine as part of the
conditioning regimen, who developed irreversible, lethal
neurotoxicity. The clinical and imaging findings resem-
bled those of ATL and were distinct from the neurological
complications, of both toxic and infectious etiology. The
authors concluded that these cases were tentatively attrib-
utable to fludarabine-specific neurotoxicity.
On the clinical and imaging field, the case we are here
reporting bears strict resemblance to the three cases
described by Lee [4]. Moreover, it shares the clinical pic-
Figure 3. Subsequent CT scan showing symmetric, hypodense
periventricular lesions.
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ture with the cases reported in phase I/II studies [13, 23–
25]:
(a) clinical onset occurred 1 month after the end of flu-
darabine administration;
(b) sensitive and cognitive impairment were the out-
standing clinical features;
(c) some imbalance was evident between the polymor-
phic severe clinical pattern and the relatively limited
extension of the white matter signal alterations;
(d) the clinical course was progressive and irreversible;
(e) the MRI pattern was indistinguishable from that
reported by Lee and collaborators, [4] and strictly remi-
niscent of ATL;
(f) a toxic rather than inflammatory etiology was
strongly suggested by the MRI findings;
(g) although the patients had refused cerebrospinal fluid
examination, PET scan and virological negativity did not
support an alternative etiology;
(h) the deep location of the white matter lesions was
not coherent with a diagnosis of PRES as a possible alter-
native diagnosis.
A final matter of discussion may be the possible role of
thiotepa. Thiotepa is known to pass through the blood
brain barrier and to have the potential of causing neuro-
toxicity. Nevertheless, the available data concern either
the intrathecal [35] or the high-dose administration
within myeloablative conditioning regimens followed by
autologous stem cell transplantation commonly used in
patients with CNS malignancies, notably lymphomas [36].
In both settings, reports involved heavily pretreated
patients where CNS irradiation and disease progression
exerted a primary role in determining the appearance of
neurological impairment [37]. Unlike fludarabine, no sug-
gestive imaging counterpart of thiotepa neurotoxicity has
been proposed thus far [36, 37]. On the clinical field, a
motor impairment seems more likely attributable to
direct thiotepa toxicity [38]. This reinforces the opinion
that our patient did suffer of fludarabine neurotoxicity.
According to Lee and colleagues [4], after ruling out
more obvious etiology of brain impairment, a fludara-
bine-related toxic etiology is strongly suspected for severe
CNS complications and the MRI pattern defined as ATL
may represent the characteristic imaging counterpart. On
the other hand, Beitinjaneh and coworkers [3] suggested
that fludarabine may also be involved in the pathogenesis
of a proportion of more benign neurologic complications
presenting as PRES at MRI; besides, ATL may also be
potentially reversible in a proportion of cases. Last but
not least, a 10% crude rate of neurotoxicity, mostly
benign and reversible, was also reported in old series with
standard dose fludarabine [2, 27], before the matter began
to be somewhat overlooked.
The case of our patient reinforces the opinion that
ATL may be the MRI counterpart of severe fludarabine
neurotoxicity, rarely observed after standard dose treat-
ment. Because irreversible ATL could only represent the
tip of an iceberg, we suggest that fludarabine neurotoxic-
ity should be taken into account also in cases of benign,
reversible neurologic impairment.
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